Your Search Results

Other right-sided and tricuspid valve interventions

20 May 2026 – From EuroPCR 2026

This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.

Imaging and physiology integration to guided PCI

20 May 2026 – From EuroPCR 2026

Discover the integration of imaging and physiological assessment in guiding percutaneous coronary intervention (PCI). This session highlights the use of multimodality diagnostics, including invasive and non-invasive techniques, to improve planning, strategy, and management of complex coronary lesions.

Complication one: PCI complications occuring during urgent PCI for NSTEMI

20 May 2026 – From EuroPCR 2026

Examine real-world PCI complications encountered during urgent interventions for NSTEMI patients. This session presents a series of complex cases illustrating management strategies for adverse events such as coronary perforations, device issues, and imaging challenges to inform safer procedural practice.

Fighting intracardiac masses

21 May 2026 – From EuroPCR 2026

This session focuses on the percutaneous management of intracardiac masses, presenting innovative approaches such as angiovac-assisted vegetation removal, management of mechanical mitral valve complications, and treatment options for right ventricular tumors. It also evaluates the emerging role of percutaneous therapies in infective endocarditis involving TAVI valves...

Complex patients with NSTEMI

20 May 2026 – From EuroPCR 2026

This session addresses the complexity of managing NSTEMI patients with challenging clinical presentations, including concurrent vessel and valve disease, thrombus burden, and atypical angiographic findings. It offers practical strategies for diagnosis and intervention to optimize patient outcomes.

Imaging-guided calcified lesion PCI

21 May 2026 – From EuroPCR 2026

This session presents state-of-the-art imaging-guided interventions for calcified coronary lesions, showcasing modalities such as lithotripsy, rotational atherectomy, and complex calcium modification techniques. It includes case studies highlighting zero-contrast PCI and stenting in challenging anatomies, including left main bifurcation lesions in elderly patients with complex clinical backgrounds.

Atypical STEMI presentations

20 May 2026 – From EuroPCR 2026

Investigate atypical presentations of STEMI and the unique challenges they pose in clinical management. This session covers case studies including high bleeding risk patients, mechanical complications post-surgery, spontaneous coronary artery dissection, and recurrent events, emphasizing tailored therapeutic approaches.

CTO PCI: understand it, love it

21 May 2026 – From EuroPCR 2026

This educational session provides a comprehensive overview of chronic total occlusion (CTO) PCI, elucidating key procedural steps, essential materials, and potential complications. It highlights the significant role of nurses and allied health professionals in supporting the procedure and enhancing patient experience throughout the pre-, intra-, and...

MASTER-DAPT: “the MASTER of high-bleeding risk trials”

28 Aug 2021

Marco Valgimigli (Lugano, Switzerland) presented the results of the MASTER DAPT trial on Saturday, August 28, in a Hot Line session of the ESC Congress 2021. Luis G. Ortega-Paz provides his PICOT & SWOT analysis of this study.

Author

Luis Ortega-Paz

ESC Congress 2021 - MASTER-DAPT : “the MASTER of high-bleeding risk trials”

On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

05 Mar 2023

Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Author

Mirvat Alasnag

$On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial$

SMT’s Hydra TAVR Valve demonstrates sustained safety, durability, and hemodynamic performance at 5 Years

19 Nov 2025

TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

04 Nov 2024

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali